{"url_path":"/sec/imdx/8-k/2026-06-17/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1642380/0001493152-26-029078-index.html","accession_number":"0001493152-26-029078","cik":"0001642380","ticker":"IMDX","issuer_name":"Insight Molecular Diagnostics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1642380/0001493152-26-029078-index.html","primary_entity_key":"0001642380","primary_entity_name":"Insight Molecular Diagnostics Inc."},"word_count":101,"has_tables":true,"body_markdown":"**Item\n9.01. Financial Statements and Exhibits**\n\n \n\n(d)\nExhibits.\n\n \n\n**Exhibit\nNo.**\n** **\n**Description**\n\n**10.1#**\n \n[Second Amendment to the Insight Molecular Diagnostics Inc. Amended and Restated 2018 Equity Incentive Plan](ex10-1.htm)\n\n**104**\n \nCover\nPage Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n#\nThe referenced exhibit is a management contract, compensatory plan or arrangement.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**INSIGHT\nMOLECULAR DIAGNOSTICS INC.**\n\n \n \n \n\nDate:\nJune 17, 2026\nBy:\n*/s/\nPeter Hong*\n\n \nName:\nPeter\nHong\n\n \nTitle:\nVice\nPresident, General Counsel"}